Register a trial

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02984566


Additional trial details provided through ANZCTR are available at the end of this record.


Registration number
NCT02984566
Ethics application status
Date submitted
23/11/2016
Date registered
7/12/2016

Titles & IDs
Public title
Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Scientific title
LARK: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)
Secondary ID [1] 0 0
TROG1703 LARK
Universal Trial Number (UTN)
Trial acronym
TROG1703 LARK
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Liver Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Liver
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Devices - Kilovoltage Intrafraction Monitoring

Experimental: SABR with or without KIM - All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.


Treatment: Devices: Kilovoltage Intrafraction Monitoring
KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Difference in accumulated patient dose distribution with and without KIM
Timepoint [1] 0 0
15-60 minutes (time of individual fraction delivery)
Secondary outcome [1] 0 0
Difference in treatment time with and without KIM
Timepoint [1] 0 0
15-60 minutes (time of individual fraction delivery)
Secondary outcome [2] 0 0
Difference in imaging dose with and without KIM
Timepoint [2] 0 0
15-60 minutes (time of individual fraction delivery)
Secondary outcome [3] 0 0
Difference in PTV margins with and without KIM
Timepoint [3] 0 0
15-60 minutes (time of individual fraction delivery)
Secondary outcome [4] 0 0
Difference in accumulated patient dose distribution with and without KIM based on the intra-treatment CBCT scans
Timepoint [4] 0 0
15-60 minutes (time of individual fraction delivery)
Secondary outcome [5] 0 0
Change in dose when using KIM with and without using MLC tracking
Timepoint [5] 0 0
15-60 minutes (time of individual fraction delivery
Secondary outcome [6] 0 0
Proportion of local failures at two years for patients treated
Timepoint [6] 0 0
2 years
Secondary outcome [7] 0 0
The proportion of grade 3 or higher toxicities
Timepoint [7] 0 0
2 years
Secondary outcome [8] 0 0
Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Core-30 (EORTC QLQ-C30)
Timepoint [8] 0 0
2 years
Secondary outcome [9] 0 0
Patient-reported quality of life as measured by the European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Hepatocellular Carcinoma 18 Module (EORTC QLQ-HCC18)
Timepoint [9] 0 0
18 months

Eligibility
Key inclusion criteria
* ECOG performance status 0-1
* Life expectancy >6 months
* Number of lesions: = 3
* Lesion size : < 10 cm for a single lesion (and up to 10 cm cumulative diameter for multiple lesions)
* Child-Pugh A or B7 within 6 weeks prior to study entry
* Unsuitable for RFA or resection or transplant
* Distance from GTV to luminal structures (i.e., oesophagus, stomach, duodenum, small or large bowel) = 10mm
* All blood work obtained within 6 weeks prior to study entry with adequate organ function
* May have had previous surgery, RFA or ethanol injection
* Patient must have been discussed at multidisciplinary tumour board with consensus opinion for SBRT
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* HCC/cholangiocarcinoma with evidence of metastatic disease including nodal or distant metastases
* Metastatic disease with complete liver disease response to first-line chemotherapy (i.e. no target for SBRT)
* Previous radiation to the liver (including SIRTEX)
* Untreated HIV or active hepatitis B/C
* On systemic antineoplastic drug therapy within 7 days before inclusion
* Pregnant or lactating women

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
14/01/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2025
Actual
Sample size
Target
Accrual to date
Final
32
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Nepean Hospital - Penrith
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
2750 - Penrith
Recruitment postcode(s) [2] 0 0
2049 - Westmead
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3000 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
University of Sydney
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tim Wang, Dr
Address 0 0
Westmead Hospital
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Anonymised data will be made available to researchers upon request, once evidence of ethical approval has been provided.
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT02984566

Additional trial details provided through ANZCTR
Accrual to date
Recruiting in Australia
Recruitment state(s)
NSW
Funding & Sponsors
Primary sponsor
University
Primary sponsor name
University of Sydney
Primary sponsor address
Commercial Developments & Industry Partnerships,
F23 Administration Building,
Corner of Eastbourne and City Road,
The University of Sydney, NSW 2006 Australia
Primary sponsor country
Australia
Ethics approval
Ethics application status
Approved
 
Public notes

Contacts
Principal investigator
Title 49 0
Dr
Name 49 0
Tim Wang
Address 49 0
Western Sydney Local Health District Cnr of Hawkesbury & Darcy Rd Westmead NSW 2145
Country 49 0
Australia
Phone 49 0
+61 2 9845 9636
Fax 49 0
Email 49 0
Tim.Wang1@health.nsw.gov.au
Contact person for public queries
Title 50 0
Ms
Name 50 0
Shona Silvester
Address 50 0
ACRF Image X Institute Room 214, Biomedical Building - C81 The University of Sydney NSW 2006
Country 50 0
Australia
Phone 50 0
+61 2 8627 1185
Fax 50 0
Email 50 0
shona.silvester@sydney.edu.au
Contact person for scientific queries
Title 51 0
Prof
Name 51 0
Paul Keall
Address 51 0
ACRF Image X Institute Suite 201, Biomedical Building - C81 The University of Sydney NSW 2006
Country 51 0
Australia
Phone 51 0
+61 2 8627 1159
Fax 51 0
Email 51 0
Paul.Keall@sydney.edu.au